The standard treatment of LBC A/B includes endocrine therapy targeting ER to inhibit tumor growth, with selective estrogen receptor modulators (tamoxifen), aromatase inhibitors (letrozole and anastrozole), and selective estrogen receptor degraders (fulvestrant and elacestrant). Here, ESR1 is linked to neoplasm.